Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
A major challenge for the next generation of human immunodeficiency virus (HIV) vaccines is the induction of potent, broad, and durable cellular immune responses. The structural protein Gag is highly conserved among the HIV type 1 (HIV-1) gene products and is believed to be an important target for the host cell-mediated immune control of the virus during natural infection. Expression of Gag proteins for vaccines has been hampered by the fact that its expression is dependent on the HIV Rev protein and the Rev-responsive element, the latter located on the env transcript. Moreover, the HIV genome employs suboptimal codon usage, which further contributes to the low expression efficiency of viral proteins. In order to achieve high-level Rev-independent expression of the Gag protein, the sequences encoding HIV-1(SF2) p55(Gag) were modified extensively. First, the viral codons were changed to conform to the codon usage of highly expressed human genes, and second, the residual inhibitory sequences were removed. The resulting modified gag gene showed increases in p55(Gag) protein expression to levels that ranged from 322- to 966-fold greater than that for the native gene after transient expression of 293 cells. Additional constructs that contained the modified gag in combination with modified protease coding sequences were made, and these showed high-level Rev-independent expression of p55(Gag) and its cleavage products. Density gradient analysis and electron microscopy further demonstrated that the modified gag and gag protease genes efficiently expressed particles with the density and morphology expected for HIV virus-like particles. Mice immunized with DNA plasmids containing the modified gag showed Gag-specific antibody and CD8(+) cytotoxic T-lymphocyte (CTL) responses that were inducible at doses of input DNA 100-fold lower than those associated with plasmids containing the native gag gene. Most importantly, four of four rhesus monkeys that received two or three immunizations with modified gag plasmid DNA demonstrated substantial Gag-specific CTL responses. These results highlight the useful application of modified gag expression cassettes for increasing the potency of DNA and other gene delivery vaccine approaches against HIV.
zur Megede
J
J
Chiron Corporation, Emeryville, California 94608, USA.
Chen
M C
MC
Doe
B
B
Schaefer
M
M
Greer
C E
CE
Selby
M
M
Otten
G R
GR
Barnett
S W
SW
D016915:AIDS Vaccines / Q000235:genetics* / Q000276:immunology; D000818:Animals; D019556:COS Cells; D002461:Cell Line, Transformed; D004279:DNA, Viral / Q000276:immunology; D005260:Female; D015870:Gene Expression; D015683:Gene Products, gag / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology; D016333:HIV Protease / Q000235:genetics; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008253:Macaca mulatta; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011498:Protein Precursors / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics* / Q000276:immunology; D014771:Virion
D016915:AIDS Vaccines; D004279:DNA, Viral; D015683:Gene Products, gag; D015483:HIV Antibodies; D011498:Protein Precursors; D019444:Vaccines, DNA; C059767:p55 gag precursor protein, Human immunodeficiency virus 1; D016333:HIV Protease